MedTrace Logo

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

NCT05263583 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-01-14

No results posted yet for this study

Summary

This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma

Conditions

  • High-grade B-cell Lymphoma
  • Burkitt Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphatic Diseases
  • Lymphoma, High-Grade
  • C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
  • C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma
  • C-Myc Gene Rearrangement

Interventions

DRUG

Sepantronium Bromide

continuous intravenous infusion

Sponsors & Collaborators

  • Cothera Bioscience, Inc

    lead INDUSTRY

Principal Investigators

  • Vernon Jiang, PhD · Cothera Bioscience

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-09
Primary Completion
2025-03-01
Completion
2025-06-30
FDA Drug
Yes

Countries

  • China
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05263583 on ClinicalTrials.gov